Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the treatment, but they regained control upon restarting it.

Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and achievement of remission.

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique ...

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only ...

This year the biosimilars to Stelara (ustekinumab) stand to be the stars of the biosimilars show. The FDA has approved seven ...

The patient was receiving mesalazine and 6-mercaptopurine and, 2 months before admission, had stopped a 4-month therapy course with the biologic agent adalimumab for treatment of Crohn's disease.

Blue Shield of California is bypassing traditional pharmacy benefit managers to offer a Humira (adalimumab)-referenced biosimilar named Idacio to patients at the lowest list price currently ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

Friday, Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), announced the FDA approved Simlandi (adalimumab-ryvk) injection ...

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...